培美曲塞联合卡铂治疗老年晚期非鳞非小细胞肺癌临床疗效分析

目的评价培美曲塞联合卡铂治疗老年晚期非鳞非小细胞肺癌的临床疗效及毒副作用。方法92例晚期非鳞非小细胞肺癌老年患者，其中培美曲塞联合卡铂（Pc组）治疗42例，吉西他滨联合卡铂（GC组）治疗50例。结果Pc组和GC组疾病控制率（DCR）为73．8％及70．2％（P〉0．05）。PC组毒副反应发生率小于GC组。结论培美曲塞联合卡铂治疗老年晚期非鳞非小细胞肺癌的疗效与吉西他滨联合卡铂的疗效相当，但副作用明显减少，患者耐受性更好。

Clinical study of pemetrexed combined with carboplatin as the first-line treatment of senile patients with advanced non-squamous non-small cell lung cancer

Objective To evaluate the curative effect and toxicity of pemetrexed combined with earboplatin as the first-line treatment of senile patient with advanced non-squamous non-small cell lung cancer. Methods 92 patients with advanced non - squamous non - small cell lung cancer were divided into two groups. The PC group （42 cases） were treated with pemetrexed combined with carboplatin, and the GC group （ 50 cases） were treated with gemcitabine combined with carboplatin. Results The disease control rate was 73.8% in the PC group and 70.2% in the GC group （P 〉0. 05 ）, but the incidence of side effects was significantly lower in the PC group than in the GC group. Conclusion Pemetrexed combined with carboplatin has the similar curative effect with gemcitabine combined with carbopl- atin in treatment of senile patient with advanced non - squamous non - small cell lung cancer, but it has less side effects and better toler- ance than gemcitabine combined with carboplatin.